The Leading Community for Trusted Peptide Research & Insights
Research summaries, dosing protocols, and community reports for peptides. Built on clinical data and real-world experiences.
Immune peptides encompass both immunostimulatory compounds (like Thymosin Alpha-1) and anti-inflammatory peptides (like KPV). They work through diverse mechanisms — from thymic hormone modulation to antimicrobial activity to cytokine regulation.
Thymosin Alpha-1 stands out with the strongest clinical evidence, having been approved in over 30 countries for hepatitis and as an immune adjuvant. Other peptides in this category are at earlier stages of research but show promising immunomodulatory properties.
Thymosin Alpha-1 has the strongest clinical evidence for immune support, with FDA orphan drug status and approval in 30+ countries. It enhances T-cell function, dendritic cell maturation, and has been studied as an adjunct in cancer immunotherapy and chronic infections.
KPV is a tripeptide (Lys-Pro-Val) derived from alpha-MSH with potent anti-inflammatory properties. It has been studied for inflammatory bowel conditions, skin inflammation, and general immune modulation. It can be administered orally, subcutaneously, or topically.
LL-37 is an antimicrobial peptide (AMP) naturally produced by the human immune system. It has direct antimicrobial activity against bacteria, viruses, and fungi, plus immunomodulatory effects. It's being researched as a potential alternative or adjunct to conventional antibiotics.